Who is this relevant for?
- Manufacturers evaluating market entry for rare disease therapies
- Hospitals managing supply risk for new treatments
- Clinical research organizations designing rare disease trials
Priovant Therapeutics ran the longest and largest interventional study in dermatomyositis. The VALOR trial enrolled patients with an ultra-rare autoimmune condition affecting five to 10 people per million per year. Brepocitinib 30 mg hit its primary endpoint and all nine key secondary endpoints. The FDA granted Priority Review with a PDUFA date in Q3 2026.
But the operational story is how Priovant got there.
The company chose a 52-week placebo-controlled design, longer than previous 16- or 24-week trials. FDA regulators recommended the longer endpoint. The tradeoff: asking severely ill patients to risk a year on placebo. Priovant mitigated this by allowing rescue therapy and counting rescued patients as non-responders. Patient retention stayed high.
CEO Ben Zimmer credits the retention to a culture of intensity and hands-on leadership. He warns against over-delegation to vendors or within the sponsor. Rare disease trials need an "artisan's touch" at every step. Site selection, patient screening, and assessments require deeply invested experts.
Digital tools helped, but the most effective tool was built in-house. Still, the trial relied on patients already under the care of expert physicians. Referrals from digital tools played a secondary role.
Priovant worked with patient advocacy groups and physician thought leaders from day zero. Direct relationships with sites, not intermediated by vendors, allowed rapid problem-solving of micro-bottlenecks.
For sponsors running rare disease phase 3 trials, the lesson is clear: stay hands-on. A 9-to-5 mindset will fail. Top executives must be engaged in the daily execution, not removed.
The VALOR trial shows that rigorous, patient-centered design combined with obsessive operational focus can overcome the barriers of ultra-rare disease research.